The FDA has approved these medications for chronic weight management in adults with obesity (body mass index 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
By inhibiting the reuptake of norepinephrine, tesofensine increases its concentration in the synaptic cleft, leading to increased activation of norepinephrine receptors
5 Another small 2024 study in Menopause showed that postmenopausal women with overweight or obesity lost 12 percent of their initial body weight on semaglutide
Nausea is most pronounced during the initial weeks of GLP-1 treatment and typically diminishes significantly after 24 weeks as your body adapts to the medication
PlexusDx helps patients build this context through provider partnerships and optional genetic insights, supporting informed conversations about whether compounded semaglutide aligns with your health profile
Curr Opin Mol Ther 12:790797 Onge EL, Miller SA (2010) Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes
